OBJECTIVES: To perform comparative pharmacoeconomic study of the application of IV generation of pancreatin drugs in patients with pancreatic exocrine insufficiency on the hospital stage of medical care. METHODS: A pharmacoeconomic model of administration of IV generation of pancreatin drugs (creon and ermital) in adult patients (100 persons in compared groups) during replacement therapy of pancreatic functional insufficiency was developed. Dosage of the drugs was at least 100 000 units of lipolytic activity per 24 h. Time horizon was 21 days. Measures of clinical efficiency of the applied therapy were the number of patients, who would reach clinical response according to „pain relief” and „diarrhea relief” parameters.  RESULTS: In the modeled conditions, costs of drug therapy per patient were within the range of 962.78 — 1,869.56 RUB in the group of creon and 736.12 — 1,237.20 for ermital, depending on the dose. CER values were: pain relief in the range of 1,046.5 — 2,032.13 in creon group, and 836.50 — 1,405.90 in ermital group; diarrhea relief was in the range of 927.38 — 1,927.38 in creon group and 783.10 — 1,316.17 in ermital group. CONCLUSIONS: The conducted clinical and economical research demonstrated pharmacoeconomic advantages of ermital administration. It should be noted that the results of this work were significantly influenced by the applied dosages of medications, which were one of the key factors of economical substantiation of use of the considered medical technologies.